ClinicalTrials.gg
Not yet recruitingNCT07264140AIMO COPDUpdated May 14, 2026

Assessing and Improving Misuse of Inhalers in COPD Outpatients

An interventional study of Physiotherapist-Led Inhaler Optimization Program in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Hôpital Fribourgeois. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Hôpital Fribourgeois · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland — 15 open to participants now, 20 under way, 2 of them phase 3. Pulmonary Disease, Chronic Obstructive · Switzerland.

Planned enrollment
32nd of 77
116 · median 74
Started
2026
with 6 others
No phase
46 of 99
8 open now
Primary completion
2029-05
later than 19 of 19 live
Registered
96th of 99
by date
Lead sponsor
2 of 99
Hôpital Fribourgeois

Among the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, this one is the 32nd largest by planned enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2026, is one of 46 with no phase, reaches primary completion later than 19 of the 19 other live ones, and was the 96th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

15 of the 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Pulmonary Disease, Chronic Obstructive with a site in Switzerland, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is a common long-term lung disease that causes breathlessness, cough, and frequent flare-ups. Most patients with COPD use inhaled medications every day. However, many people do not use their inhalers correctly, or they cannot generate the right inspiratory flow for their device. When inhalers are used incorrectly, the medication does not reach the lungs properly, symptoms worsen, and the risk of exacerbations increases.

This pragmatic randomized controlled trial evaluates whether a structured physiotherapist-led inhaler optimization program improves inhaler use in routine outpatient COPD care. The program is delivered by trained physiotherapists over 12 months and includes three in-person sessions. During these sessions, the physiotherapist evaluates the patient's inhaler technique using placebo devices, measures the patient's peak inspiratory flow with the In-Check DIAL® device, and provides individualized "teach-to-goal" education to help patients use their inhalers correctly. If the patient continues to make critical errors or cannot generate the appropriate inspiratory flow for their inhaler, the physiotherapist may recommend adapting the type of inhaler to better match the patient's abilities.

Participants will be randomly assigned to one of two groups. The intervention group will receive the structured program in addition to their usual COPD care. The control group will continue with usual outpatient care without the physiotherapist-led sessions. All participants will complete baseline and 12-month assessments, which include inhaler technique evaluation, inspiratory flow measurement, respiratory questionnaires, and lung function tests. Telephone follow-up calls will be performed at months 2, 5, and 8 to monitor symptoms, inhaler use, and adherence.

The main outcome of the study is the proportion of inhalers used incorrectly at 12 months. Incorrect use is defined as at least one critical inhaler technique error or an inspiratory flow that is too low or too high for the patient's device. Secondary outcomes include changes in respiratory symptoms, health status, adherence to inhaled treatment, patient satisfaction with inhalers, confidence in inhaler use, and the number of COPD exacerbations or hospitalizations during the study.

This research may help improve everyday inhaler use in people with COPD and support more personalized inhaler selection in routine clinical care. Although participants may not benefit directly, the study poses minimal risks and may contribute to future improvements in COPD management.

Read the detailed description

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Most patients rely on inhaled medications to control symptoms and reduce the risk of exacerbations. However, many patients do not use their inhalers correctly. Critical errors-such as incorrect preparation of the device, improper inhalation technique, or an inspiratory flow that is not appropriate for the device-are common and can lead to reduced drug delivery, poorer symptom control, and more frequent exacerbations. Previous studies conducted at the study site have shown that nearly 70% of hospitalized COPD patients used at least one inhaler incorrectly. In addition, peak inspiratory flow (PIF) varies between individuals, and many patients are unable to generate the flow required for certain dry powder inhalers. Despite this, regular assessment of inhaler technique and inspiratory flow is not systematically implemented in outpatient practice.

This randomized controlled trial evaluates whether a structured, physiotherapist-led inhaler-optimization program can reduce incorrect inhaler use among outpatients with COPD. The intervention includes three face-to-face visits over 12 months. During these sessions, physiotherapists trained in inhaler technique assessment use device-specific placebo inhalers and standardized checklists to identify critical errors. They also measure PIF with the In-Check DIAL® device, adjusted to the resistance of each patient's inhaler. The physiotherapist then provides individualized "teach-to-goal" education, with demonstration, correction, and repeated practice until mastery of the inhaler technique is achieved. When persistent errors or suboptimal PIF are identified, the physiotherapist informs the treating physician to consider adapting the type of inhaler.

Participants are randomly assigned (1:1) to the intervention group or the usual-care group. Usual care consists of regular management by the treating physician, which may include inhaler review at the physician's discretion, but without the structured physiotherapist-led sessions. Both groups undergo baseline and 12-month assessments that include inhaler technique evaluation using placebo devices, PIF measurement, respiratory questionnaires, and pulmonary function testing. Participants in both groups also receive telephone follow-up calls at months 2, 5, and 8 to assess symptoms, inhaler use, adherence, and confidence in inhaler use.

The primary endpoint is the proportion of misused inhalers at 12 months. An inhaler is considered misused if the patient demonstrates at least one critical technique error or if their measured PIF is outside the recommended range for their specific device. This composite outcome captures both aspects of inhaler adequacy: correct handling of the device and physiological ability to use it effectively. Because participants may use more than one inhaler device, the primary outcome is assessed at the inhaler level while accounting for clustering within participants. Secondary endpoints include changes in health status measured by validated respiratory questionnaires (CAT and CCQ), treatment adherence using the TAI questionnaire, satisfaction with inhalers, confidence in inhaler use, pulmonary function parameters, and the number of COPD exacerbations and hospitalizations over the 12-month follow-up.

The trial uses a pragmatic design to reflect real-world outpatient care. The inhaler-optimization program is intended to be simple, scalable, and easily integrated into routine COPD management. The educational approach is based on individualized instruction and repeated reinforcement, which patients in prior studies have reported as highly valuable. Outcome assessment at 12 months is performed by assessors who are not involved in delivering the intervention and are instructed to remain blinded to group allocation.

The study is minimal-risk and non-invasive. Potential risks include temporary fatigue or coughing during repeated inspiratory maneuvers and the time required for study visits and follow-up calls. The intervention does not involve investigational products or exposure to radiation. Data are collected according to Swiss data protection regulations using coded identifiers and secure REDCap databases.

By evaluating inhaler technique and inspiratory flow in a structured, standardized manner, this study aims to provide new evidence on how to improve inhaler use in COPD. Results may support more personalized device selection, enhance patient education practices, and reduce COPD exacerbations and associated healthcare burden. The findings may be applicable to a wide range of outpatient settings and could inform future guidelines on inhaler optimization in chronic respiratory diseases.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • COPD
  • Chronic Obstructive Pulmonary Disease
  • Inhaler Technique
  • Inhaler Misuse
  • Peak Inspiratory Flow
  • Inhaler Education
  • Inhaler Optimization
  • Respiratory Physiotherapy
  • In-Check DIAL
  • Outpatient COPD Care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. confirmed by spirometry (/FVC \<0.7)
  3. Current use of at least one maintenance inhaler
  4. Follow-up at the outpatient pneumology clinic of HFR Fribourg
  5. Ability to provide written

Exclusion criteria

Exclusion Criteria:

  1. Inability to provide (e.g. severe cognitive impairment, advanced psychiatric disorder, unresolved language barrier)
  2. \<12 months
  3. Predominant other chronic lung disease (e.g. asthma, fibrosis)
  4. Any condition preventing completion of study procedures
  5. Ongoing participation in another interventional trial on inhaler technique
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants receive a structured, physiotherapist-led inhaler-optimization program in addition to their usual COPD care. The program includes three in-person visits at approximately Months 3, 6, and 9. During each visit, the physiotherapist assesses inhaler technique using device-specific placebo inhalers, measures peak inspiratory flow (PIF) with the In-Check DIAL® device, and provides individualized teach-to-goal inhaler education. If persistent critical errors or suboptimal PIF are identified, a recommendation is made to the treating physician to adapt the inhaler type. All participants undergo baseline and 12-month assessments identical to the control group.

    Behavioral: Physiotherapist-Led Inhaler Optimization Program

  • No intervention
    Usual Outpatient COPD Care

    Participants receive standard outpatient COPD management from their treating physician. Usual care may include medication adjustments and inhaler review at the physician's discretion, but no structured physiotherapy sessions are added. Participants complete baseline and 12-month assessments identical to the intervention group, including inhaler technique evaluation, PIF measurement, respiratory questionnaires, and lung function testing.

Interventions

  • BehavioralPhysiotherapist-Led Inhaler Optimization Program

    This intervention consists of a structured, physiotherapist-led inhaler-optimization program delivered over 12 months in addition to usual outpatient COPD care. Participants attend three face-to-face sessions at Months 3, 6, and 9. During each session, a trained physiotherapist evaluates inhaler technique using device-specific placebo inhalers and validated checklists, measures peak inspiratory flow (PIF) with the In-Check DIAL® device adjusted to the resistance of each inhaler, and provides individualized teach-to-goal education with iterative demonstration and feedback until correct technique is achieved. If the participant continues to demonstrate critical errors or cannot generate an adequate PIF for their prescribed device, the physiotherapist notifies the treating physician and recommends adapting the inhaler type. The intervention does not include medication changes or pharmacologic treatment.

06

What researchers measure

Primary outcomes

  1. Proportion of Misused Inhalers at 12 Months

    An inhaler is classified as misused if the participant demonstrates at least one critical inhaler technique error or if the measured peak inspiratory flow (PIF) is outside the recommended range for the specific device. Critical errors are assessed using device-specific standardized checklists with placebo inhalers. PIF is measured using the In-Check DIAL® device set to the resistance of each inhaler. The first PIF measurement, reflecting the participant's usual inhalation technique, is used to classify misuse. Device-specific thresholds define insufficient PIF for dry powder inhalers and excessive PIF for pMDIs or soft-mist inhalers. The analysis will be conducted at the inhaler level using statistical methods accounting for clustering of inhalers within participants.

    Time frame: Month 12

Secondary outcomes

  1. Prevalence of critical inhaler technique errors at 12 months

    Critical inhalation technique error, defined as an error likely to result in insufficient delivery of medication to the lungs. Errors will be assessed using device-specific standardized checklists, based on validated reference frameworks identifying critical steps for each inhaler type. The analysis will be conducted at the inhaler level using statistical methods accounting for clustering of inhalers within participants.

    Time frame: Month 12

  2. Prevalence of inadequate Peak Inspiratory Flow at 12 months

    Suboptimal Peak Inspiratory Flow is measured using the In-Check DIAL® set to the resistance corresponding to the patient's inhaler. For dry powder inhalers, Peak Inspiratory Flow values below the device-specific recommended threshold will be considered insufficient. For pressurized metered-dose inhalers or soft mist inhalers, PIF values above the recommended range will be considered excessive. The first measurement reflects the patient's actual inhalation performance in routine conditions and is therefore used to classify misuse. Threshold values will be based on published device-specific recommendations. The analysis will be conducted at the inhaler level using statistical methods accounting for clustering of inhalers within participants.

    Time frame: Month 12

  3. Change in COPD Assessment Test (CAT) Score

    Change in health status measured with the COPD Assessment Test (CAT), a validated 8-item questionnaire (score range 0-40, higher scores indicate worse symptoms). The change from baseline to Month 12 will be compared between groups.

    Time frame: Baseline and Month 12

  4. Change in Clinical COPD Questionnaire (CCQ)

    Change in health status measured with the Clinical COPD Questionnaire (CCQ), a validated 10-item questionnaire. Each item is scored on a seven-point Likert scale ranging from 0 (no impairment) to 6 (maximal impairment). The overall score corresponds to the mean of all item scores and therefore ranges from 0 to 6, with higher values indicating worse disease control and greater functional limitation. The change from baseline to Month 12 will be compared between groups.

    Time frame: Baseline and Month 12

  5. Change in Adherence to Inhaled Therapy (TAI Score)

    Change in adherence measured with the Test of Adherence to Inhalers (TAI), a validated tool assessing intentional and unintentional non-adherence. Total score 10-50, higher scores indicate better adherence.

    Time frame: Baseline and Month 12

  6. Change in Patient Satisfaction With Inhalers (FSI-10 Score)

    Satisfaction with inhaler devices assessed using the 10-item Feeling of Satisfaction with Inhaler (FSI-10) questionnaire. Higher scores indicate greater satisfaction.

    Time frame: Baseline and Month 12

  7. Change in Confidence in Inhaler Use

    Change in confidence using a 7-point Likert-type scale ranging from 1 (no confidence) to 7 (complete confidence). Measured at baseline and Month 12 to assess improvement in inhaler self-efficacy.

    Time frame: Baseline and Month 12

  8. Change in Pulmonary Function Parameters

    Change in post-bronchodilator FEV₁ (liters and % predicted), FEV₁/FVC ratio, and FEF25-75%, measured according to ATS/ERS standards. Comparison of changes from baseline to Month 12 between groups.

    Time frame: Baseline and Month 12

  9. Time to First COPD Exacerbation

    Time from randomization to the first COPD exacerbation requiring systemic corticosteroids, with or without antibiotics. Exacerbations are confirmed through medical records or treating physician.

    Time frame: Up to 12 months

  10. Time to First Severe COPD Exacerbation

    Time to first severe COPD exacerbation, defined as a COPD exacerbation requiring emergency department visit or hospitalization.

    Time frame: Up to 12 months

  11. Time to First COPD-Related Hospitalization

    Time from randomization to the first unplanned hospital admission for a COPD exacerbation, confirmed through discharge documentation.

    Time frame: Up to 12 months

Other outcomes

  1. Change in the proportion of misused inhalers within the control group

    Within the control group, the change in the proportion of misused inhalers between baseline and Month 12 will be analyzed to assess the effect of a standardized pneumology consultation alone.

    Time frame: Baseline and Month 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results will be made available upon reasonable request after publication of the primary study results. The study protocol, informed consent form, statistical analysis plan, and analytic code will also be available upon reasonable request. Requests should be directed to the corresponding investigator and will be reviewed in accordance with institutional policies and applicable Swiss data protection regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: De-identified individual participant data and supporting documents will be available beginning 6 months after publication of the primary study results and will remain available for at least 5 years thereafter upon reasonable request.

Access criteria: Access to de-identified individual participant data and supporting documents (study protocol, statistical analysis plan, informed consent form, and analytic code) will be granted to qualified researchers whose proposed use of the data is methodologically sound and consistent with the aims of the study. Requests should be directed to the corresponding investigator and will be reviewed by the study team in accordance with institutional policies and applicable Swiss data protection regulations. Data will be shared in a de-identified format after approval of a data access request and, if required, after signature of a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for May 2029, 35 months later.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 35 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 4, 2025
StartEst.
Jun 1, 2026
Primary completionEst.
May 31, 2029
CompletionEst.
Dec 31, 2029
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07264140
Lead sponsor
Hôpital Fribourgeois
Responsible party
Sponsor
First posted
Dec 4, 2025
Start date
Jun 1, 2026 (estimated)
Primary completion
May 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 14, 2026

Study contacts

Gaël Grandmaison, MD
Contact
gael.grandmaison@h-fr.ch
+41 26 306 23 68
Sandrine Foucras
Contact
sandrine.froucras@h-fr.ch
+ 41 26 306 21 06

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion